A new study has devised a new type of chimeric antigen-receptor (CAR) T cell — a family of promising immunotherapies for cancer — that can be switched on and off on demand.
A new study has devised a new type of chimeric antigen-receptor (CAR) T cell — a family of promising immunotherapies for cancer — that can be switched on and off on demand.